Trifarotene

Drug Profile

Trifarotene

Alternative Names: CD-5789

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Galderma
  • Developer Galderma; University of Texas M. D. Anderson Cancer Center
  • Class Antiacnes; Antineoplastics; Benzoic acids; Keratolytics; Pyrrolidines; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ichthyosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Ichthyosis
  • No development reported Cutaneous T cell lymphoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma(Early-stage disease) in USA (Topical, Cream)
  • 01 Nov 2015 Galderma initiates enrolment in a phase III trial for Acne vulgaris (In children, In adolescents, In adults) in USA (NCT02556788)
  • 01 Oct 2015 Galderma plans a phase III trial for Acne vulgaris (In children, In adolescents, In adults) in Canada and USA (NCT02566369)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top